Returned medicines

Returned investigational products should be clearly identified and stored in a dedicated area Inventory records of returned medicinal products should be kept The responsibilities of the investigator and... 

Ms. Davis was prescribed meclizine (A ntivert-50) 50 mg for motion sickness. On return from a long car ride die tells you that the medicine did not help. Explain what questions you would ask to determine if Ms. Davis followed the prescribed drug regimen. 

If your symptoms (and peak flow, if used) return to GREEN ZONE after 1 hour of above treatment IQ Take the quick-relief medicine every 4 hours for 1 to 2 days. 

Kaptchuk returned from China a proponent of acupuncture and wrote The Web That Has No Weaver, the classic explanation of Chinese medicine for Western readers.3 But over time he came to wonder whether the effects of acupuncture might be at least partly due to the placebo effect. To answer that question, he taught himself how to design research studies, and he did so well enough to obtain funding from the National Institutes of Health and publish more than ioo articles in leading medical journals. No wonder Harvard saw fit to hire and promote him, despite his rather unusual academic credentials. 

Three submarkets of the pharmaceutical market can be distinguished innovative patented products sold by prescription, products whose patent has expired and are sold by prescription, and products sold without a prescription. The public regulation of prices in the first of these submarkets, and often also in the second, is a fact that can be observed in most Western countries, with certain notable exceptions such as the USA. Concern about the particular characteristics of the pharmaceutical market (for example, the existence of patents and the pharmaceutical industry s rate of return), together with the desire to provide the majority of the population with access to medicines, regardless of their ability to pay (in many countries the public sector is the main buyer in this market), has led to the fairly widespread adoption of more or less strict price intervention and control policies for pharmaceuticals. 

If products under patent are exempted from the RP system, do the negative effects on the R D of the pharmaceutical sector disappear The exclusion of medicines with a current patent may reduce the economic erosion of the rights granted by the patent, and also the disincentive to invest in R D. But negative effects on innovation are not totally eradicated, as (a) RP increases the uncertainty on the expected return on the investment, (b) incentives for innovation will be damaged due to the fact that the R D process is a joint production process, since the overall return is reduced when RP is applied, and (c) the exclusion of patented products has proved to be only partial in some cases (for example, not excluding drags under a process patent). 

Systems with freedom of prices These are the countries in which pharmaceutical companies are free to fix the price they see fit for their medicines. This is the case in the USA and the UK. However, freedom of prices does not mean the absence of any type of regulation. Thus, in the UK the Pharmaceutical Price Regulation Scheme6 establishes limits to the return that can be obtained by the companies. Indirectly, this limits the price of the drags. 

Physicians who have drug problems sometimes use a process called harvesting in order to obtain the medications for their own personal use. Harvesting occurs when a physician (seemingly innocendy) asks a patient to return any unused pain or other type of mood-altering medications to the physician. The physician will tell a patient that this is for his or her protection to take away the threat of accidental use of the medicines by someone in the household. The physician will offer to dispose of the medicine properly so that it is out of the household. However, the medicines will likely be used by the physician instead of being wasted. Patients should understand that since they have paid for (or their insurance has paid for) those medicines, it is unethical for a physician to ask for them in the first place, and such a request should warn of a problem. 

The fluorescence and phosphorescence of luminescent materials are modulated by the characteristics of the environment to which these materials are exposed. Consequently, luminescent materials can be used as sensors (referred also as transducers or probes) to measure and monitor parameters of importance in medicine, industry and the environment. Temperature, oxygen, carbon dioxide, pH, voltage, and ions are examples of parameters that affect the luminescence of many materials. These transducers need to be excited by light. The manner in which the excited sensor returns to the ground state establishes the transducing characteristics of the luminescent material. It is determined by the concentration or value of the external parameter. A practical and unified approach to characterize the luminescence of all sensors is presented in this chapter. This approach introduces two general mechanisms referred as the radiative and the nonradiative paths. The radiative path, in the general approach, is determined by the molecular nature of the sensor. The nonradiative path is determined by the sensor environment, e.g., value or concentration of the external parameter. The nonradiative decay rate, associated with the nonradiative path, increases... 

Many compounds in the top decile of the returns distribution involve the first mover, or other early entrants, in a new therapeutic class. The family of medicines in a given... 

Of every 5000 medicines tested, on average, only 5 are tested in clinical trials and only 1 of those is approved for patient use." Very, very few biotech concepts yield commercial returns. Consequently, investors are hypersensitive to events which appear to shift the odds of success one way or the other. What drives biotech stock prices up or down is not changes in timelines, but rather changes in perceptions of the risk of failure. 

There has been a revival in the use of traditional medicine (TM) in the last decade. TM is also called complementary or alternative medicine (CAM). It is likely that this revival trend will continue when there are still unmet needs to be hlled by Western drugs. The quandary with Western drugs is that pharmaceutical hrms have to ensure a reasonable return on shareholders investment. With many drug discovery and development programs costing billions of dollars, most pharmaceutical firms concentrate on blockbuster drugs with large market potential. The way is thus left open for the treatment of many diseases by other means such as TM. 

The discovery of insulin at the University of Toronto in 1921-22 was one of the most dramatic events in the history of the treatment of disease. Insulin s impact was so sensational because of the incredible effect it had on diabetic patients. Those who watched the first starved, sometimes comatose, diabetics receive insulin and return to life saw one of the genuine miracles of modem medicine. They were present at the closest approach to the resurrection of the body that our secular society can achieve, and at the discovery of what has become the elixir of life for millions of human beings around the world. 

---